Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Partial enteral nutrition combined with an exclusion diet promotes a healthy gut microbiome in patients with mild to moderately active ulcerative colitis: a quasi-experimental study.

Crohn's & colitis 360·2026
Same author

Meta-Analysis: Crohn's Disease Exclusion Diet for Induction and Maintenance in Crohn's Disease.

Alimentary pharmacology & therapeutics·2026
Same author

Home-prepared prednisolone enema in ulcerative colitis: Outcomes from a real-world case series.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

The impact of global recruitment and country income on placebo rates in inflammatory bowel disease clinical trials.

Journal of Crohn's & colitis·2026
Same author

Basal plasmacytosis and eosinophilia for distinguishing inflammatory bowel disease from gastrointestinal tuberculosis on mucosal biopsy.

Journal of clinical pathology·2026
Same author

Defining Research Priorities in Nutrition and Inflammatory Bowel Disease: Insights From the Nutrition and IBD Research Group.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Videos

Proton pump inhibitors: concerns over prolonged use.

V Pratap Mouli1, Vineet Ahuja

  • 1Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi - 110029, India.

Tropical Gastroenterology : Official Journal of the Digestive Diseases Foundation
|February 16, 2012
PubMed
Summary

Proton pump inhibitors (PPIs) are frequently overprescribed, and recent reports suggest significant adverse events. This review examines the evidence linking PPIs to these potential risks.

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Drug Safety

Background:

  • Proton pump inhibitors (PPIs) are widely used and generally considered safe.
  • Concerns have emerged regarding potential adverse events associated with PPI use.
  • The clinical significance and evidence base for these adverse events require thorough evaluation.

Purpose of the Study:

  • To review and synthesize the available evidence on adverse events linked to proton pump inhibitors.
  • To assess the clinical significance of reported adverse events associated with PPIs.
  • To highlight areas where further research is needed to confirm the PPI-adverse event linkage.

Main Methods:

  • Literature review of published studies and case reports.
  • Analysis of clinical evidence supporting the association between PPIs and adverse events.

Related Experiment Videos

  • Assessment of biological plausibility for reported adverse events.

    • Main Results:

    • While PPIs are extensively prescribed, evidence suggests potential links to significant adverse events.
    • The biological plausibility for some adverse events is recognized.
    • Further clinical studies are necessary to definitively confirm the causal relationship between PPIs and adverse events.

    Conclusions:

    • The widespread use of proton pump inhibitors warrants careful consideration of their safety profile.
    • Emerging evidence suggests potential adverse events that require further investigation.
    • Confirmation of the clinical evidence linking PPIs to adverse events is crucial for clinical practice.